Cellipont Bioservices
Cellipont Bioservices is a privately held, B2B cell therapy CDMO founded in 2006 and headquartered in The Woodlands, Texas, providing cGMP process development and manufacturing services for autologous and allogeneic cell therapies to clinical-stage biotech and pharmaceutical clients.
- Company typePrivate
- Founded2002
- HeadquartersPoway, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cellipont Bioservices does
Cellipont Bioservices is a privately held cell therapy Contract Development and Manufacturing Organization (CDMO) founded in 2006 and headquartered in The Woodlands, Texas. The company provides process development, analytical development, technology transfer, and cGMP clinical and commercial manufacturing services for autologous and allogeneic cell therapies — including CAR-T, iPSC-derived therapies, exosomes, mesenchymal stem cells (MSCs), macrophage, dendritic cell, and TCR-T programs — to clinical-stage biotechnology and pharmaceutical clients. Cellipont operates a 76,000 sq. ft. purpose-built manufacturing facility with 7 clean rooms, QC labs, temperature-controlled storage, and — as of December 2025 — a ballroom-style cleanroom equipped with a 50-liter single-use bioreactor for large-scale allogeneic production. Its technology stack integrates the ADVA X3 automated cell therapy manufacturing platform (the first North American CDMO deployment), the L7|ESP unified Manufacturing Execution System from L7 Informatics, and the Xiogenix Ares X20 fill-finish system.
The company's commercial model is B2B fee-for-service CDMO engagement: project-based, quote-negotiated contracts with biotech and pharma sponsors. Revenue is generated through development services, technology transfer projects, and clinical and commercial manufacturing campaigns. Cellipont sells through a dedicated enterprise commercial team (Chief Commercial Officer Edwin Beale, with VP and Senior Director of Business Development) targeting clinical-stage cell therapy developers, supported by industry conference participation (ASGCT, ISCT, BIO, MESA), PR, LinkedIn, and the corporate website. The company is majority-owned by Great Point Partners (GPP), with a minority growth equity investment from HealthQuest Capital (October 2024) and prior strategic debt financing from OrbiMed (2023). The named customer base spans at least 12 clinical-stage biotechs (Marker Therapeutics, Wugen, Secretome Therapeutics, Diakonos Oncology, Ernexa Therapeutics, Optieum Biotechnologies, BobcatBio, Mongoose Bio, Soter Bio, Applied StemCell, Ronawk, CellVax Therapeutics), with most engagements at Phase I clinical manufacturing stage and a 2026 collaboration extending Cellipont's scope into GMP RNA biomolecule manufacturing.
Cellipont Bioservices firmographics
Firmographics- Name
- Cellipont Bioservices
- Legal name
- Cellipont Bioservices
- Website
- https://cellipont.com/
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cellipont Bioservices is a privately held, B2B cell therapy CDMO founded in 2006 and headquartered in The Woodlands, Texas, providing cGMP process development and manufacturing services for autologous and allogeneic cell therapies to clinical-stage biotech and pharmaceutical clients.
- Ownership category
- akta.pro rank
Cellipont Bioservices industry classification
Industry- Product category
- Cell Therapy CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Cellipont Bioservices is headquartered
LocationHeadquarters
- HQ city
- Poway
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cellipont Bioservices business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Cellipont operates as a Contract Development and Manufacturing Organization (CDMO) providing fee-for-service development and manufacturing to biotech/pharma clients. Revenue generated through project-based contracts for process development, analytical services, technology transfer, and cGMP manufacturing of cell therapies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Cellipont Bioservices product offering
Product offeringCore offering
Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides fee-for-service process development, analytical development, technology transfer, and cGMP manufacturing of cell therapies including CAR-T, allogeneic, autologous, iPSC-derived therapies, and exosomes. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas with seven cleanrooms, integrated QC labs, and advanced closed processing systems, serving biotech and pharmaceutical clients from early process development through commercial manufacturing.
Product overview
Cellipont Bioservices is a premier cell therapy Contract Development and Manufacturing Organization (CDMO) offering a comprehensive suite of manufacturing services. The company's service portfolio includes CAR-T Services, Allogeneic Cell Therapy, Autologous Cell Therapy, iPSC Services, and Exosome Manufacturing. These services are supported by integrated capabilities spanning Process Development & Analytical Development, Clinical Manufacturing, Quality Control, and Quality & Compliance. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas featuring 7 clean rooms, QC labs, and advanced closed processing systems. Cellipont also offers technology access partnerships including the ADVA X3® automated manufacturing platform and Xiogenix Ares™ X20 fill-finish system.
Differentiator
Problem solved
Functional benefit
Products and services
- CAR-T Services Comprehensive CAR-T cell therapy development and manufacturing services for biotech and pharmaceutical clients, spanning process development through commercial manufacturing of chimeric antigen receptor T-cell therapies.
- Allogeneic Cell Therapy Development and manufacturing services for allogeneic (off-the-shelf) cell therapies derived from healthy donor cells, supporting biotech and pharmaceutical clients with large-scale commercial production capabilities.
- Autologous Cell Therapy Personalized autologous cell therapy manufacturing services using a patient's own cells, providing cGMP manufacturing for biotech and pharmaceutical clients developing patient-specific cell therapies.
- iPSC Services Induced pluripotent stem cell (iPSC) development and manufacturing services for cell therapy applications, supporting biotech and pharmaceutical clients developing iPSC-derived therapies.
- Exosome Manufacturing cGMP exosome manufacturing services for therapeutic applications, providing biotech and pharmaceutical clients with scalable production of exosome-based therapeutics.
- Process Development and Analytical Development Comprehensive process development and analytical method development services for cell therapy manufacturing, enabling clients to optimize production processes and establish analytical methods for cell therapy products.
- Clinical Manufacturing cGMP clinical manufacturing services supporting biotech and pharmaceutical clients through early to late-stage clinical trial supply of cell therapy products at the purpose-built The Woodlands, Texas facility.
- Quality Control Quality control testing services for cell therapy products, ensuring safety, purity, and potency of client products through integrated QC labs at the cGMP manufacturing facility.
- Quality and Compliance Regulatory compliance and quality assurance services meeting global GMP standards for cell therapy manufacturing clients.
Quantifiable outcome
- Cell and gene therapy manufacturing market projected to reach USD 146.2 billion by 2032
- +1 more outcomes
Companies that use Cellipont Bioservices
Customer profileNamed customers12 records
Segments1 record
Ideal customer profiles1 record
Cellipont Bioservices technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Cellipont Bioservices partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core.
- Applied StemCellcoreStrategic collaboration to provide integrated iPSC-derived cell therapy development services, combining ASC's GMP iPSC lines and TARGATT gene editing technology with Cellipont's cGMP manufacturing and regulatory expertise. Aims to reduce technical risk and shorten development timelines by connecting upstream cell engineering with late-stage manufacturing.
- BobcatBiocoreStrategic collaboration to advance macrophage-based cell therapy RB-1355 for solid tumors. Cellipont will perform Phase I cell product manufacturing in support of BobcatBio's ongoing solid tumor and lymphoma clinical trials.
- Soter BiocoreStrategic collaboration for integrated U.S. cell therapy and RNA biomolecule manufacturing. Cellipont provides GMP cell therapy manufacturing and regulatory support while Soter Bio supplies GMP RNA and biomolecule manufacturing capabilities. Aims to accelerate development timelines and strengthen domestic manufacturing resilience.
- RonawkcoreStrategic partnership to accelerate scalable expansion of high-quality mesenchymal stem cells (MSCs). Combines Cellipont's cGMP manufacturing expertise with Ronawk's Bio-OS platform to address industry challenges in scalability, consistency, and cost-effectiveness for MSC-based therapies.
- Ernexa TherapeuticscoreManufacturing partnership to advance ERNA-101 cell therapy for ovarian cancer into clinical trials. Focuses on manufacturing process development supporting clinical trial preparations for Ernexa's synthetic allogeneic stem cell therapy platform.
- Marker TherapeuticscoreCollaboration for cGMP manufacturing of MT-601 multi-antigen recognizing T cell therapy for patients with lymphoma. Cellipont provides technology transfer and cGMP manufacturing to support scale-up and production for Marker Therapeutics' APOLLO study.
- Optieum BiotechnologiescorePartnership for cGMP manufacturing of OPTF01, Optieum's novel CAR-T therapy for glioblastoma treatment derived from their proprietary Eumbody System. Cellipont provides technology transfer, process development, and cGMP manufacturing.
- Secretome TherapeuticscorePartnership for cGMP manufacturing of Master Cell Bank for STM-01, a novel cell therapy derived from neonatal cardiac progenitor cells for treatment of heart failure. Cellipont provides technology transfer, analytical method transfer, and cGMP manufacturing.
- Mongoose BiocoreAgreement for Technology Transfer, Process Development, and cGMP Manufacture of MGB-001, Mongoose Bio's autologous TCR-T cell therapy program targeting solid tumors. Built on 17 years of pioneering work by founder Dr. Cassian Yee at MD Anderson.
- ADVA BiotechnologycorePartnership marking the launch of ADVA X3 platform in North America. ADVA X3 is an advanced, fully automated manufacturing platform for CAR-T and other cell therapies, streamlining processes and reducing costs. Cellipont is first CDMO in North America to offer this platform.
- WugencoreAgreement for clinical manufacture of Wugen's allogeneic, off-the-shelf CAR-T cell therapies for treatment of hematological and solid tumor malignancies. Cellipont provides technology transfer and production at their purpose-built facility.
- L7 InformaticscoreStrategic partnership deploying L7 Informatics' L7|ESP unified platform and MES application to digitalize cell therapy manufacturing recipes, streamline technology transfers, and enable end-to-end manufacturing operations.
- Diakonos OncologycoreAgreement for Process Development and cGMP Manufacturing of DOC1021, an autologous dendritic cell vaccine for treatment of glioblastoma multiforme and other cancer indications. Diakonos received FDA Fast Track designation for this therapy.
Scale indicators5 records
Recent moves11 records
Expansion highlights6 records
Cellipont Bioservices competitors and assessment
Company assessmentDirect peers
- Genezen: Cell and gene therapy CDMO offering process development, viral vector, plasmid and cell therapy GMP manufacturing. Comparable emerging cell-therapy CDMO competing for clinical-stage biotech outsourcing.
- ElevateBio: Cell and gene therapy CDMO operating BaseCamp, a centralized process development and GMP manufacturing hub for cell therapies, viral vectors and gene editing. Similar end-to-end service model targeting the same clinical-stage biotech customer set.
- Catalent Cell & Gene Therapy (formerly MaSTherCell): The most direct competitor: a cell and gene therapy CDMO offering allogeneic and autologous CAR-T manufacturing services. Cellipont's CEO, COO and CCO all previously held senior roles here, underscoring head-to-head competition for the same biotech programs.
- BioCentriq: Cell therapy CDMO offering process development, analytical and GMP manufacturing services for autologous and allogeneic cell therapies including CAR-T and iPSC. Closely comparable niche cell-therapy CDMO model.
- Lonza Cell & Gene Technologies: Global CDMO with dedicated cell and gene therapy manufacturing services, offering autologous and allogeneic cell therapy process development and GMP manufacturing. Cellipont's COO (O'Mara) and VP of Program Management (Kuzniar) both came from Lonza, indicating direct talent and customer overlap.
- Center for Breakthrough Medicines (CBM): Purpose-built cell and gene therapy CDMO offering process development, viral vector, cell therapy and plasmid manufacturing from a single King of Prussia facility. Closely comparable scale, footprint and offering mix to Cellipont's Texas facility.
- Charles River Laboratories (Cell Therapy CDMO): Provides cell therapy process development, viral vector and GMP manufacturing services to biotech and pharma clients. Operates comparable cell therapy CDMO services and competes for the same clinical-stage cell therapy outsourcing contracts.
- AGC Biologics (Cell and Gene Therapy): Global CDMO with cell therapy, viral vector and plasmid manufacturing capabilities serving biotech developers. Competes directly with Cellipont for autologous and allogeneic cell therapy CDMO engagements.
Broad incumbents
- WuXi Advanced Therapies Unit: Major global cell and gene therapy CDMO offering autologous and allogeneic cell therapy process development and GMP manufacturing. A larger incumbent with overlapping service lines; however, increasing U.S. BIOSECURE-related restrictions on WuXi materially limit their U.S. market access, which is a non-trivial tailwind for Cellipont.
- FUJIFILM Diosynth Biotechnologies: Large-scale CDMO actively expanding into cell therapy and gene therapy manufacturing alongside its biologics core. A broader incumbent that overlaps with Cellipont in cell therapy services but competes from a much larger, diversified portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cellipont Bioservices social profiles
Digital presenceCellipont Bioservices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellipont Bioservices leadership team
Management profileNumber of profiles
Profiles8 records
Cellipont Bioservices funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellipont Bioservices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellipont Bioservices
What does Cellipont Bioservices do?
Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides fee-for-service process development, analytical development, technology transfer, and cGMP manufacturing of cell therapies including CAR-T, allogeneic, autologous, iPSC-derived therapies, and exosomes. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas with seven cleanrooms, integrated QC labs, and advanced closed processing systems, serving biotech and pharmaceutical clients from early process development through commercial manufacturing.
Is Cellipont Bioservices a public or private company?
Cellipont Bioservices is a private company. It is classified as private equity controlled and is currently operating.
When was Cellipont Bioservices founded?
Cellipont Bioservices was founded in 2002. It employs 11 to 50 people.
Where is Cellipont Bioservices based?
Cellipont Bioservices is headquartered in Poway, United States, in the North America region.
How does Cellipont Bioservices make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are Cellipont Bioservices's main competitors?
Direct peers on record are Genezen, ElevateBio, Catalent Cell & Gene Therapy (formerly MaSTherCell), BioCentriq, Lonza Cell & Gene Technologies, Center for Breakthrough Medicines (CBM), Charles River Laboratories (Cell Therapy CDMO) and AGC Biologics (Cell and Gene Therapy). Broad incumbents are WuXi Advanced Therapies Unit and FUJIFILM Diosynth Biotechnologies.
Does Cellipont Bioservices have an API?
No public API is recorded for Cellipont Bioservices.
What industry is Cellipont Bioservices in?
Cellipont Bioservices's product category is Cell Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325412 and its SIC code is 2836.